Our results revealed that the ICB response scores were crucially higher in the high-risk subtype, high-DKK1 expression subtype, and high-MIF expression subtype than those in the low subtypes, which suggest poor immunotherapy efficacy for patients with HNSCC in the high-risk groups. This evidence concerns the gene MIF and head and neck squamous cell carcinoma.